Hemolytic uremic syndrome

Common Name(s)

Hemolytic uremic syndrome

Hemolytic uremic syndrome (HUS) is a condition in which red blood cells are abnormally destroyed, leading to a decreased red blood cell count (anemia) and destruction of the platelets (thrombocytopenia). Platelets are found circulating in the blood and are involved in clot formation to stop bleeding. HUS is most often caused by an infection of a certain strain of E. coli. An individual is likely to ingest E. coli, a bacterium, when eating undercooked, spoiled, or contaminated food or drinking contaminated water. Children ages 2 to 14 are most commonly affected. In adults, other causes of HUS are medications, other infections, and genetic inheritance (atypical hemolytic uremic syndrome).

HUS is often found after symptoms of bloody diarrhea and abdominal pain. Symptoms of HUS include paleness, fatigue, passing only small amounts of urine, bloody urine, stomach pain, swelling, vomiting, easy bruising, small amounts of bleeding from the mouth and nose, and fever. The debris from destroyed red blood cells in HUS can clog or damage the tiny blood vessels in the kidney, which is the organ that filters blood and produces urine. Kidney failure may occur and is a feared complication of this condition.

Diagnosis of HUS is usually made using a blood test to look at potential red blood cell damage, a urine test, and a stool test for bacteria. HUS is treated in a hospital and may involve fluid replacement, an injection of more red blood cells and/or platelets, injection of plasma (the liquid part of blood), and possibly kidney dialysis if the kidney can no longer filter blood. If you or a loved one has been diagnosed with HUS, talk to your doctor about the most current treatment options. Support groups are available for resources and more information.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hemolytic uremic syndrome" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hemolytic uremic syndrome" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Hemolytic uremic syndrome" returned 485 free, full-text research articles on human participants. First 3 results:

Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome.
 

Author(s): Yuji Yamada, Ryohei Abe, Yutaka Okano, Yoshitaka Miyakawa

Journal: Intern. Med.. 2017 ;56(9):1085-1088.

 

We experienced a favorable outcome in an adult case of atypical hemolytic uremic syndrome (aHUS) after long-term eculizumab treatment. A 38-year-old Japanese man with a history of central retinal vein occlusion was admitted to our hospital with progressive dyspnea. He was found to ...

Last Updated: 1 May 2017

Go To URL
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
 

Author(s): Timothy H J Goodship, H Terence Cook, Fadi Fakhouri, Fernando C Fervenza, Véronique Frémeaux-Bacchi, David Kavanagh, Carla M Nester, Marina Noris, Matthew C Pickering, Santiago Rodríguez de Córdoba, Lubka T Roumenina, Sanjeev Sethi, Richard J H Smith,

Journal: Kidney Int.. 2017 Mar;91(3):539-551.

 

In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement plays a primary role in disease pathogenesis. Herein we report the outcome of a 2015 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference where key issues in the management ...

Last Updated: 19 Dec 2016

Go To URL
Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome.
 

Author(s): Hong Jiang, Meng-Nan Fan, Min Yang, Chao Lu, Ming Zhang, Xiao-Hong Liu, Le Ma

Journal:

 

To evaluate the association among complement factor H-related (CFHRs) gene deficiency, complement factor H (CFH) autoantibodies, and atypical hemolytic uremic syndrome (aHUS) susceptibility. EMBASE, PubMed, and the ISI Web of Science databases were searched for all eligible studies ...

Last Updated: 8 Dec 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Hemolytic uremic syndrome" returned 58 free, full-text review articles on human participants. First 3 results:

Atypical hemolytic uremic syndrome induced by CblC subtype of methylmalonic academia: A case report and literature review.
 

Author(s): Minguang Chen, Jieqiu Zhuang, JianHuan Yang, Dexuan Wang, Qing Yang

Journal: Medicine (Baltimore). 2017 Oct;96(43):e8284.

 

Methylmalonic acidemia (MMA) is a common organic acidemia, mainly due to methylmalonyl-CoA mutase (MCM) or its coenzyme cobalamin (VitB12) metabolic disorders. Cobalamin C (CblC) type is the most frequent inborn error of cobalamin metabolism; it can develop symptoms in childhood and ...

Last Updated: 25 Oct 2017

Go To URL
Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome.
 

Author(s): Elie Azoulay, Paul Knoebl, José Garnacho-Montero, Katerina Rusinova, Gennadii Galstian, Philippe Eggimann, Fekri Abroug, Dominique Benoit, Michael von Bergwelt-Baildon, Julia Wendon, Marie Scully

Journal: Chest. 2017 Aug;152(2):424-434.

 

A typical hemolytic uremic syndrome (aHUS) presents similarly to thrombotic thrombocytopenic purpura (TTP) and other causes or conditions with thrombotic microangiopathy (TMA), such as disseminated intravascular coagulation or sepsis. Similarity in clinical presentation may hinder ...

Last Updated: 26 Apr 2017

Go To URL
A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome.
 

Author(s): Borja Quiroga, Alberto de Lorenzo, Cristina Vega, Fernando de Alvaro

Journal:

 

BACKGROUND Recent advances in the treatment of atypical hemolytic-uremic syndrome (aHUS) have resulted to better long-term survival rates for patients with this life-threatening disease. However, many questions remain such as whether or not long-term treatment is necessary in some ...

Last Updated: 15 Dec 2016

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Atypcial Hemolytic-Uremic Syndrome (aHUS) Registry
 

Status: Recruiting

Condition Summary: Atypical Hemolytic-Uremic Syndrome

 

Last Updated: 16 Oct 2017

Go to URL
A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome
 

Status: Recruiting

Condition Summary: Atypical Hemolytic Uremic Syndrome

 

Last Updated: 1 Nov 2017

Go to URL
Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
 

Status: Recruiting

Condition Summary: Atypical Hemolytic Uremic Syndrome (aHUS)

 

Last Updated: 13 Oct 2017

Go to URL